International Journal of Hematology

Papers
(The H4-Index of International Journal of Hematology is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-12-01 to 2024-12-01.)
ArticleCitations
Engineering the next generation of CAR-NK immunotherapies56
Recent advances in the research and management of sepsis-associated DIC55
Multiple myeloma with high-risk cytogenetics and its treatment approach44
Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine37
Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia36
Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment32
COVID-19 microthrombosis: unusually large VWF multimers are a platform for activation of the alternative complement pathway under cytokine storm24
Prediction of clinical outcomes through assessment of sarcopenia and adipopenia using computed tomography in adult patients with acute myeloid leukemia23
New-onset Evans syndrome associated with systemic lupus erythematosus after BNT162b2 mRNA COVID-19 vaccination23
Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma19
Eltrombopag for the treatment of poor graft function following allogeneic stem cell transplant: a retrospective multicenter study19
Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR us19
Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives18
Drug interaction between letermovir and voriconazole after allogeneic hematopoietic cell transplantation18
Comparisons of global coagulation potential and bleeding episodes in emicizumab-treated hemophilia A patients and mild hemophilia A patients17
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities17
Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?16
Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial16
Diagnostic and treatment guidelines for thrombotic thrombocytopenic purpura (TTP) in Japan 202316
0.024942874908447